Pink Sheet Podcast: Drug Fix: ALS Drug Cleared, Lecanemab’s Hopeful Alzheimer’s Data, CMS’ Price Negotiation Needs
Executive Summary
Pink Sheet reporters and editors discuss the newly approved ALS drug Relyvrio, the promising data on the Alzheimer’s drug lecanemab, and CMS’s efforts to build the drug price negotiation program.
You may also be interested in...
Pink Sheet Podcast: RSV Vaccine Questions, Lilly Lowers Insulin Cost, Orphan Drug Act Changes
Pink Sheet reporters and editors discuss US FDA advisory committee members’ concerns about two proposed RSV vaccines, Lilly’s plan to lower the cost of its insulin products, proposed changes to the Orphan Drug Act, and the departure of the influential leader of the FDA’s neuroscience office.
Publisher’s Spotlight: Citeline Awards 2023 Finalists Announced
We are delighted to announce the shortlist for the seventh annual Citeline Awards, recognizing clinical and research excellence across the biopharmaceutical, CRO and diagnostics industries.
Pink Sheet Podcast: Limiting Medicare Price Negotiation, More US FDA Adcomm And COVID-19 Vaccine Concerns
Pink Sheet reporters and editors discuss the impact of PhRMA’s new push to limit Medicare price negotiations, Congress’ interest in FDA advisory committee reforms, and concerns about the COVID-19 vaccine strain selection process.